Holen Sie sich die Stockscreener-App
24.77
0.77%
0.205
Schlusskurs vom Vortag:
$24.57
Offen:
$25.07
24-Stunden-Volumen:
5.25M
Relative Volume:
0.89
Marktkapitalisierung:
$12.38B
Einnahmen:
$4.89B
Nettoeinkommen (Verlust:
$-242.00M
KGV:
-50.66
EPS:
-0.489
Netto-Cashflow:
$315.00M
1W Leistung:
+3.25%
1M Leistung:
+10.00%
6M Leistung:
+12.60%
1J Leistung:
+84.23%
1-Tages-Spanne:
$24.66
$26.23
1-Wochen-Bereich:
$22.83
$26.23
52-Wochen-Spanne:
$13.15
$27.72
Elanco Animal Health Inc Stock (ELAN) Company Profile
Firmenname
Elanco Animal Health Inc
Sektor
Telefon
877-352-6261
Adresse
450 ELANCO CIRCLE, INDIANAPOLIS
Compare ELAN vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
24.78 | 12.27B | 4.89B | -242.00M | 315.00M | -0.489 |
TAK
Takeda Pharmaceutical Co Adr
|
15.39 | 47.49B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.33 | 38.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.945 | 38.57B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.50 | 32.53B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.50 | 23.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Citigroup | Buy |
| 2026-01-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-11-21 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2025-11-19 | Hochstufung | Argus | Hold → Buy |
| 2025-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-07-17 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-06-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-12-09 | Eingeleitet | UBS | Buy |
| 2024-12-02 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-09-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-01-05 | Hochstufung | Stifel | Hold → Buy |
| 2023-12-19 | Eingeleitet | Jefferies | Buy |
| 2023-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-07 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2023-04-20 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-08-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-07-21 | Herabstufung | Goldman | Buy → Sell |
| 2022-07-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-11-18 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-28 | Herabstufung | Stifel | Buy → Hold |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-06-15 | Hochstufung | Cleveland Research | Underperform → Neutral |
| 2021-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2021-05-11 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2021-04-15 | Eingeleitet | Stifel | Buy |
| 2021-03-22 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2021-02-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-09 | Herabstufung | Argus | Buy → Hold |
| 2020-11-09 | Herabstufung | Barclays | Overweight → Underweight |
| 2020-08-20 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-08-13 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-08-04 | Fortgesetzt | Goldman | Buy |
| 2020-07-27 | Herabstufung | Cleveland Research | Neutral → Underperform |
| 2020-04-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-10 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-19 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-11-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-23 | Eingeleitet | Barclays | Overweight |
| 2019-08-26 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-08-15 | Hochstufung | UBS | Sell → Neutral |
| 2019-05-23 | Eingeleitet | Guggenheim | Neutral |
| 2019-03-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-03-13 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-02-12 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-23 | Eingeleitet | UBS | Sell |
| 2019-01-15 | Eingeleitet | Argus | Buy |
| 2018-10-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Elanco Animal Health Inc Aktie (ELAN) Neueste Nachrichten
Elanco offers treatments for New World screwworm in U.S. livestock By Investing.com - Investing.com Canada
Elanco Animal HealthOffers Treatment Options For Livestock And Pets Against New World Screwworm - TradingView
New World screwworm reaches U.S.; Elanco offers animal treatments - Stock Titan
Elanco Animal Health Inc (ELAN) Stock Up 4.0% but GF Value Says Overvalued -- GF Score: 66/100 - GuruFocus
Survey: Pet owners maintain health spending despite rising costs - PetfoodIndustry
Jim Cramer Says He Feels 'Something Not Well' At Zoetis, Names A Rival As His Pick - Benzinga
U.S. pet owners cut dining out before pet care, Elanco finds - Stock Titan
Peak Retirement Planning Inc. Acquires Shares of 121,770 Elanco Animal Health Incorporated $ELAN - MarketBeat
Geode Capital Management LLC Buys 640,098 Shares of Elanco Animal Health Incorporated $ELAN - MarketBeat
BNP Paribas Financial Markets Purchases 2,193,391 Shares of Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco (ELAN) CFO granted new deferred stock units under compensation plan - Stock Titan
Elanco (ELAN) officer Rajeev Modi receives deferred stock unit grant - Stock Titan
Elanco (ELAN) CEO Jeffrey Simmons granted new deferred stock units - Stock Titan
Elanco (ELAN) Q1 2026 Earnings Transcript - AOL.com
Legal & General Group Plc Has $17.68 Million Stock Position in Elanco Animal Health Incorporated $ELAN - MarketBeat
A Look At Elanco (ELAN) Valuation After Early Befrena Launch And Renewed Investor Optimism - Yahoo Finance
Elanco (ELAN) Is Up 9.8% After Launching Befrena, Its Second USDA-Approved Pet Biologic - Yahoo Finance
EBIT per share of Elanco Animal Health, Inc. – LS:A2N6BH - TradingView
Barclays Maintains Elanco Animal Health(ELAN.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Ribbon cut on $200 million Elanco animal health campus - MSN
Jupiter Asset Management Ltd. Trims Stake in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Shareholders Back Board, Auditor and Executive Pay - The Globe and Mail
Jackson Creek Investment Advisors LLC Buys Shares of 65,370 Elanco Animal Health Incorporated $ELAN - MarketBeat
Royce & Associates LP Sells 107,638 Shares of Elanco Animal Health Incorporated $ELAN - MarketBeat
Northwestern Mutual Wealth Management Co. Grows Position in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health 2026 Shareholder Meeting Results: Board Elections and Executive Compensation Vote - Minichart
A Look at Elanco Animal Health Inc (ELAN) After 3.8% Gain -- GF Value $15.53 vs Price $23.69 - GuruFocus
Elanco (NYSE: ELAN) investors reelect board and ratify 2026 auditor - Stock Titan
Monumental Public-Private Initiative Forms to Permanently Close America’s Protein Gap - CSRwire
58,758 Shares in Elanco Animal Health Incorporated $ELAN Acquired by Williamson Legacy Group LLC - MarketBeat
A Look at Elanco Animal Health Inc (ELAN) After 5.0% Gain -- GF Value $15.53 vs Price $22.82 - GuruFocus
Board member at Elanco (NYSE: ELAN) granted new equity awards - Stock Titan
Elanco (NYSE: ELAN) director receives deferred and restricted stock units - Stock Titan
Elanco Animal Health (ELAN) director granted new equity awards - Stock Titan
[Form 4] Elanco Animal Health Inc Insider Trading Activity - Stock Titan
Elanco (NYSE: ELAN) director receives 4,678 deferred stock units - Stock Titan
Board member gets 4,678-share equity award at Elanco (NYSE: ELAN) - Stock Titan
Elanco (ELAN) director Harrington granted deferred and restricted stock units - Stock Titan
Elanco (ELAN) director granted stock and deferred unit awards as compensation - Stock Titan
Elanco (NYSE: ELAN) director Stacey Ma receives annual equity grants - Stock Titan
Elanco (NYSE: ELAN) director granted deferred and restricted stock units - Stock Titan
Elanco Animal Health (ELAN) Stock Analysis: Exploring Potential 37% Upside with Strong Buy Ratings - DirectorsTalk Interviews
Elanco Animal Health Incorporated (NYSE:ELAN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Q1 2026 Elanco Animal Health Inc Earnings Call Transcript - GuruFocus
Q1 Rundown: Elanco (NYSE:ELAN) Vs Other Pharmaceuticals Stocks - Yahoo Finance
ELAN Stock Price, Quote & Chart | ELANCO ANIMAL HEALTH INC (NYSE:ELAN) - ChartMill
Elanco Animal Health Inc Annual Shareholders Meeting Transcript - GuruFocus
Elanco Launches Befrena As New Dermatology Driver For Undervalued Shares - Yahoo Finance
Companion Animal Health Market is expected to Hit US$ 56.60 - openPR.com
Is Elanco Animal Health Inc (ELAN) Overvalued After 5.3% Rally? - GuruFocus
Is Elanco Animal Health Inc (ELAN) Overvalued After 5.3% Rally? GF Value Says Overvalued - GuruFocus
Finanzdaten der Elanco Animal Health Inc-Aktie (ELAN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):